GRP78 Knockdown Enhances Apoptosis via the Down-Regulation of Oxidative Stress and Akt Pathway after Epirubicin Treatment in Colon Cancer DLD-1 Cells by Chang, Yu-Jia et al.
GRP78 Knockdown Enhances Apoptosis via the Down-
Regulation of Oxidative Stress and Akt Pathway after






1Graduate Institute of Clinical Medicine College of Medicine, Taipei Medical University, Taipei, Taiwan, 2Department of Surgery, College of Medicine, Taipei Medical
University, Taipei, Taiwan, 3Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan, 4Cancer Research Center, Taipei Medical University Hospital, Taipei,
Taiwan, 5Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi City, Taiwan
Abstract
Introduction: The 78-kDa glucose-regulated protein (GRP78) is induced in the cancer microenvironment and can be
considered as a novel predictor of responsiveness to chemotherapy in many cancers. In this study, we found that
intracellular reactive oxygen species (ROS) and nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation were
higher in GRP78 knockdown DLD-1 colon cancer cells compared with scrambled control cells.
Methodology/Principal Findings: Treatment with epirubicin in GRP78 knockdown DLD-1 cells enhanced apoptosis and was
associated with decreased production of intracellular ROS. In addition, apoptosis was increased by the antioxidants propyl
gallate (PG) and dithiothreitol (DTT) in epirubicin-treated scrambled control cells. Epirubicin-treated GRP78 knockdown cells
resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3b, as well as downstream targets
of b-catenin expression. Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated
GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells. We
also demonstrated that epirubicin-treated GRP78 knockdown cells could decrease survival pathway signaling through the
redox activation of protein phosphatase 2A (PP2A), which is a serine/threonine phosphatase that negatively regulates the
Akt pathway.
Conclusions: Our results indicate that epirubicin decreased the intracellular ROS in GRP78 knockdown cells, which
decreased survival signaling through both the Akt pathway and the activation of PP2A. Together, these mechanisms
contributed to the enhanced level of epirubicin-induced apoptosis that was observed in the GRP78 knockdown cells.
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Introduction
GRP78 is a chief regulator of endoplasmic reticulum (ER)
function. The roles of GRP78 include (1) protein folding and
assembly, (2) targeting misfolded protein for degradation, and (3)
ER Ca
2+-binding and control of the activation of transmembrane
ER stress sensors. Moreover, due to its anti-apoptotic property,
GRP78 is induced in a wide variety of cancer cells and drug-
resistant cancer cells [1]. Interestingly, GRP78 expression is
significantly stronger in colon cancer than in colon adenoma and
normal tissue [2]. In addition, a recent study showed that GRP78
knockdown not only efficiently suppressed the proliferation of
RKO colon cancer cells but also induced the early apoptosis of the
cells [3]. Moreover, GRP78 downregulation has been shown to
result in colon cancer sensitization to paclitaxel-induced apoptosis
[4]. Taken together, these reports highlight the important role of
GRP78 in therapeutic treatment.
Several anticancer agents result in oxidative stress by producing
reactive oxygen species (ROS) and inducing cytotoxicity and
apoptosis in cancer cells [5]. Oxidative stress that occurs during
chemotherapy, however, may interfere with the cytotoxic effects of
anticancer agents, which depend on the rapid proliferation of
cancer cells for optimal activity [5]. Other studies have also
illustrated that moderate oxidative stress can stimulate the
proliferation and survival of cancer cells through conditioning
mechanisms, whereas the enhancement of ROS overproduction
by prooxidants under severe oxidative stress can result in apoptosis
and cell death [6]. In redox signaling, Nrf2 plays a critical role in
the transcription of a series of genes that contribute to phase II/III
enzymes and the defense against oxidative stress [7]. There is
increasing evidence for frequent mutations of Nrf2 in human
cancers, which result in a large amount of Nrf2 nuclear
translocation and lead to the constitutive expression of cytopro-
tective and detoxification genes. The growth advantages and
resistance to apoptosis provided by these genes provide chemo-
resistance during therapy [8]. Other reports have also illustrated
that treatment with chemotherapeutic drugs activates the Nrf2
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chemosensitivity in colon cancer cells [9]. Therefore, the inhibition
of Nrf2 nuclear translocation can be presumed to suppress cell
proliferation and enhance apoptosis in cancers. Taken together,
these studies show that oxidative stress and redox regulation play
important roles in chemotherapy.
Akt is an apoptotic regulator that is activated in many cancers
and may promote drug resistance in vitro [10]. Survival signals
induced by various receptors are primarily mediated by Akt; thus,
the Akt pathway may promote resistant phenotypes [11]. The
recurrent deregulation of the Akt survival signaling pathway in
cancers has resulted in significant interest among researchers
attempting to block this pathway for treatment purposes [12].
Hence, inhibition of the Akt pathway is being considered as a
novel strategy to sensitize cancer cells to anticancer drugs [13].
Epirubicin is a doxorubicin derivative anthracycline analog that
has a better therapeutic index than doxorubicin [14]. With the
same dose, epirubicin elicits lower hematologic and cardiac
toxicity than doxorubicin [15]. The mechanism of epirubicin on
cytotoxicity appears to involve the production of ROS [16]. To
date, the detailed anticancer mechanism of epirubicin in GRP78
knockdown colon cancer cells has not been elucidated. In the
present study, we were interested in understanding the anticancer
effect of epirubicin on the apoptotic potential of GRP78
knockdown in human colon DLD-1 cancer cells. We were also
interested in understanding the apoptotic mechanism of GRP78
knockdown on oxidative stress, redox regulation and the Akt
survival pathway during epirubicin treatment so that a guide may
be developed for additional antineoplastic therapeutics for human
colon cancers.
Materials and Methods
Cell line, reagents and chemicals
The human colon cancer cell line DLD-1 was obtained from the
Bioresource Collection and Research Center (Hsinchu, Taiwan).
RPMI-1640 medium and fetal bovine serum (FBS) were obtained
from Hyclone (South Logan, UT) and Gibco Inc. (Freehold, NJ),
respectively. Arrest-In transfection agent was obtained from Open
Biosystems Inc. (Huntsville, AL). The Nrf2 siRNA, scrambled
siRNA, primary antibodies against p-Akt (Thr308), Akt, Nrf-2,
GSK-3b, b-catenin, SP-1 and GAPDH were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). The Akt kinase assay
kit was acquired from Cell Signaling Technology (Boston, MA).
The Bio-Rad protein assay reagent was purchased from Bio-Rad
Laboratories (Richmond, CA). The Ser/Thr phosphatase assay kit
was purchased from Millipore Corporation (Billerica, MA). Propyl
gallate (PG), dithiothreitol (DTT), propidium iodide (PI), 29,79-
dichlorodihydrofluorescein diacetate (DCFH-DA), DNase-free
RNase A, dimethyl sulfoxide (DMSO), trypan blue, anti-actin
primary antibody and other chemicals were purchased from
Sigma Chemical Co. (St. Louis, MO).
Cell culture and treatment
DLD-1 cells were cultured in RPMI-1640 medium containing
10% FBS. The stock solution of epirubicin was dissolved in
DMSO, and the treated concentration (500 ng/ml) was prepared
in RPMI-1640 medium.
Generation of GRP78 knockdown DLD-1 cells
The expression of GRP78 was knocked down in DLD-1 cells
with siRNA. Briefly, the target sequence for the human GRP78
mRNA was 59-AAGGTTACCCATGCAGTTGTT-39. The
scrambled siRNA sequence was 59-AAGGTGGTTGTTTTGTT-
CACT-39. The GRP78 siRNA and scrambled siRNA were
inserted into the pSUPERIOR vector and transfected into the
DLD-1 cells. Cells that were successfully transfected and were
selected by antibiotic resistance as previously described [17–19]. In
the present study, the DLD-1 cells transfected with GRP78 siRNA
were named GRP78 knockdown cells, and the DLD-1 cells
transfected with scrambled siRNA were named scrambled control
cells. The expression of GRP78 in the scrambled control cells and
the GRP78 knockdown cells was evaluated by western blotting.
Cell viability assay
Cell viability was evaluated by the trypan blue exclusion assay.
Cells (1610
6) were cultured in 60-mm tissue culture dishes for
24 h. The culture medium was replaced with new medium, and
the cells were exposed to epirubicin for 48 h. After treatment, a
mixture was made with 1 part 0.4% trypan blue and 1 part cell
suspension. The mixture was then incubated for approximately
3 min at room temperature, a drop of the trypan blue/cell mixture
was applied to a hemacytometer and the unstained (viable) and
stained (nonviable) cells were separately counted in the hemacy-
tometer.
DNA damage and cell cycle analysis
DNA damage and the cell cycle were evaluated by PI staining
and flow cytometry. Cells (1610
6) were cultured in 60-mm tissue
culture dishes overnight. The culture medium was replaced with
fresh medium, and the cells were treated with epirubicin for 48 h.
After treatment, the cells were collected, washed with phosphate-
buffered saline (PBS), fixed in PBS-methanol (1:2, volume/
volume) solution, and maintained at 4uC for at least 18 h. After
one PBS wash , the cell pellets were stained with a PI solution
(PBS, 40 mg/ml PI, and 40 mg/ml DNase-free RNase A) for
30 min at room temperature in the dark and analyzed by a
Becton-Dickinson FACScan flow cytometer (Franklin Lakes, NJ).
At least 10,000 cells were counted per sample, and the DNA
histograms were further evaluated using Modfit software on a PC
workstation to calculate the percentage of cells in the various
phases of the cell cycle and to quantify the cells with DNA damage
(subG1 phase).
Intracellular ROS measurement
The production of intracellular ROS was detected by flow
cytometry using DCFH-DA. After treatment, the cells were
washed once with PBS, treated with 20 mM DCFH-DA for
30 min in the dark, washed again with PBS, collected by
centrifugation, and suspended in PBS. Intracellular ROS levels,
which were indicated by the fluorescence of dichlorofluorescein
(DCF), were measured through a 530/22-nm barrier filter using a
Becton-Dickinson FACScan flow cytometer.
Nrf2 siRNA transfection
To silence the gene expression of Nrf2, three sets of siRNA
oligonucleotides were designed: (1) 59-GCAUGCUACGUGAU-
GAAGAtt-39 (sense) and 59-UCUUCAUCACGUAGCAUGCtt-
39 (antisense); and (2) 59-CUCCUACUGUGAUGUGAAAtt-39
(sense) and 59-UUUCACAUCACAGUAGGAGtt-39 (antisense);
and (3) 59-GUGUCAGUAUGUUGAAUCAtt-39 (sense) and 59-
UGAUUCAACAUACUGACACtt-39 (antisense). The cells
(4610
5) were cultured in 60-mm dishes in 5 ml of RPMI-1640
medium complemented by 10% FBS and transfected at 40%
confluency by adding Arrest-In transfection agent (Huntsville, AL)
and Nrf2 siRNA. Control cells were treated with Arrest-In
transfection agent and the scrambled siRNA [59-UUCUCC-
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GUUCGGAGAATT-39 (antisense)], which did not lead to the
specific degradation of any cellular messages. Cells were rinsed
with medium after 25 min of incubation and then maintained in
culture for an additional 24 h. The nuclear Nrf2 expression was
evaluated by western blotting.
Akt kinase activity assay
Akt kinase activity was detected using the nonradioactive Akt
kinase assay kit. Briefly, cells cultured in 60-mm dishes were
treated with 500 ng/ml epirubicin or vehicle as control. After
epirubicin treatment, the cells were washed twice with ice-cold
PBS and harvested with a cell lysis buffer [20 mM Tris (pH 7.5),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM
sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM
Na3VO4, and 1 mg/ml leupeptin]. The protein content was
measured using a Bio-Rad protein assay reagent. Akt kinase was
immunoprecipitated from the cell extract (300 mg of protein) using
a bead-conjugated phospho-Akt (Ser473) rabbit monoclonal
antibody and incubated with gentle rocking overnight at 4uC.
The pellets were washed two times with a cell lysis buffer and then
washed twice with 500 m1 of kinase buffer. The pellets were
suspended in 50 ml of kinase buffer supplemented with 1 mlo f
10 mM ATP and an appropriate quantity of kinase substrate
(GSK-3 fusion protein) for 30 min at 30uC. The reaction was
terminated with 25 mlo f3 6SDS sample buffer. Phosphorylation
of GSK-3 fusion protein was detected by western blotting with
antiphospho-GSK-3a/b (Ser21/9) rabbit monoclonal antibody.
Protein phosphatase 2A (PP2A) activity assay
PP2A activity was assayed using the Ser/Thr phosphatase assay
kit. Briefly, the cells were lysed with the lysis buffer as suggested by
the protocol included in the kit. An aliquot corresponding to 50 mg
of protein was used to evaluate the PP2A activity using the
protocol from the manufacturer. The absorbance of the reaction
solution was measured in 96-well plates at 405 nm in a microplate
reader (Bio-Rad, Richmond, CA).
Western blotting analysis
After treatment, the cells were washed with PBS, resuspended in
a protein extraction buffer for 10 min, and centrifuged at 120006
g for 10 min at 4uC to obtain the extracted proteins (supernatant).
Protein concentrations were measured with a Bio-Rad protein
assay reagent. The extracted cellular proteins were boiled in
loading buffer, and an aliquot corresponding to 50–100 mgo f
protein was separated on a 12% SDS-polyacrylamide gel. After
electrophoresis, the proteins were electrotransferred onto a
polyvinylidene fluoride transfer membrane. After blotting, the
membranes were incubated with various primary antibodies
overnight and then washed with PBST solution (0.05% Tween
20 in PBS). Following washing, the secondary antibody, which was
labeled with horseradish peroxidase, was added to the membrane
for 1 h and then washed with PBST solution (0.05% Tween 20 in
PBS). The antigen-antibody complexes were detected by enhanced
chemiluminescence (Amersham Pharmacia Biotech, Piscataway,
NJ) with a chemiluminescence analyzer.
Statistical analysis
Data are presented as the mean 6 standard deviation from at
least three independent experiments and were analyzed using
Student’s t tests. A P value of less than 0.05 was considered
statistically significant [20].
Results
GRP78 knockdown enhanced the cell death and
apoptosis induced by epirubicin treatment
Figure 1A shows the expression of GRP78 in the scrambled
control DLD-1 cells and GRP78 knockdown DLD-1 cells.
GRP78 knockdown DLD-1 cells showed a lower expression of
GRP78 than the scrambled control DLD-1 cells. We further
evaluated cell viability and apoptosis after epirubicin treatment in
the GRP78 knockdown and scrambled control DLD-1 cells.
Figure 1B shows that cell viability was significantly decreased in
the GRP78 knockdown cells compared with the scrambled
control cells after 48 h of 500 ng/ml epirubicin treatment. In
addition, the apoptosis percentage of the GRP78 knockdown cells
(83.17%) was much higher than the percentage observed in the
scrambled control cells (35.12%) 48 h after epirubicin treatment
(Figure 1C). These results suggest that GRP78 is a target protein
for epirubicin-induced cell death and apoptosis in DLD-1 colon
cancer.
GRP78 knockdown reduced epirubicin-induced
intracellular ROS
To evaluate the intracellular oxidative stress, intracellular ROS
were evaluated by DCFH-DA staining in the scrambled control
cells and the GRP78 knockdown cells. Figure 2A shows that the
GRP78 knockdown cells exhibited 7- to 10 -fold greater DCF
fluorescence than the scrambled control cells after 24–48 h of
culture, which indicated that significant oxidative stress existed in
the GRP78 knockdown cells. Treatment of the scrambled control
cells with epirubicin resulted in ROS increases of 1.3- and 1.5-fold
at 24 and 48 h compared with scrambled control cells without
epirubicin (Figure 2B). In contrast, intracellular ROS were
decreased by 0.65- and 0.81-fold in the epirubicin-treated
GRP78 knockdown cells at 24 and 48 h compared with GRP78
knockdown cells without epirubicin (Figure 2B). The dose of
epirubicin over than 500 ng/ml did not increase the ROS in the
GRP78 knockdown DLD-1 cells. Epirubicin inhibited the ROS in
a dose-dependent manner in the GRP78 knockdown DLD-1 cells
(Figure 2C). These results suggest that intracellular ROS reduction
might enhance apoptosis in epirubicin-treated scrambled control
cells. When the antioxidants PG and DTT, which are used to
decrease intracellular ROS, were added to the epirubicin-treated
scrambled control cells, apoptosis was increased from 35.12% to
53.18% and 83.06%, respectively (Figure 2D). Interestingly,
neither PG nor DTT alone could induce apoptosis in the
scrambled control cells.
Nrf2 is involved in the defense mechanism in the GRP78
knockdown cells
Nrf2 is a transcription factor that responds to intracellular
ROS stimulation and translocates to the nucleus by binding the
antioxidant response element and transcribing phase II enzymes.
We studied Nrf2 nuclear translocation in the scrambled control
cells and the GRP78 knockdown cells. Figure 3A shows that
Nrf2 nuclear translocation increased approximately 1.6-fold in
the GRP78 knockdown cells compared with the scrambled
control cells. We also evaluated whether Nrf2 nuclear translo-
cation played a defensive role against epirubicin-induced
apoptosis in the GRP78 knockdown cells. The GRP78
knockdown cells were treated with Nrf2 siRNA for 24 h to
inhibit Nrf2 expression prior to incubation with epirubicin for
48 h. After the epirubicin incubation, apoptosis was evaluated by
flow cytometry. Figure 3B shows that, Nrf2 expression was
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cells, and Figure 3C shows that apoptosis was significantly
increased by Nrf2 siRNA treatment in the epirubicin-treated
GRP78 knockdown cells, which indicates that Nrf2 provided an
important defense mechanism when GRP78 was knocked down
in the DLD-1 cells.
Figure 1. Analysis of GRP78 expression, cell viability and apoptosis. (A) Analysis of GRP78 expression in the scrambled and GRP78
knockdown DLD-1 cells by western blotting. Analysis of (B) cell viability and (C) apoptosis after treatment with vehicle (control) and epirubicin (epi).
Scrambled control and GRP78 knockdown DLD-1 cells were treated with epirubicin (500 ng/ml) for 48 h. Cell viability was evaluated by the trypan
blue exclusion assay. The percentages of cells that were in the subG1 phase (indicated by DNA damage) were determined as outlined in the Materials
and Methods. The values are represented as the mean 6 standard deviation (n=5–8) of the individual experiments. Significant differences for the
control group and the scrambled control group are P,0.05 (*) and P,0.05 (#), respectively. These experiments were performed at least 3 times, and
a representative experiment is presented.
doi:10.1371/journal.pone.0035123.g001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35123Figure 2. The effect of intracellular oxidative stress on epirubicin (epi) treatment. Scrambled control and GRP78 knockdown DLD-1 cells
were (A) cultured for 24 and 48 h or (B) treated with epirubicin (500 ng/ml) for 24 or 48 h. (C) GRP78 knockdown DLD-1 cells were treated with
epirubicin (500, 750, 1000 ng/ml) for 48 h. Intracellular ROS were evaluated by DCFH-DA staining and flow cytometry as outlined in the Materials and
Methods. (D) Scrambled control DLD-1 cells were treated with 500 ng/ml epirubicin (epi) alone, 25 mM propyl gallate (PG) alone, 1 mM dithiothreitol
(DTT) alone or epirubicin combined with PG or DTT for 48 h . The percentages of cells that were in the subG1 phase (indicated by DNA damage) were
determined as outlined in the Materials and Methods. The values are represented as the mean 6 standard deviation (n=5–8) of the individual
experiments. A significant difference from the control group was set at P,0.05 (*).
doi:10.1371/journal.pone.0035123.g002
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inhibition of the Akt pathway
There is increasing evidence that the Akt pathway provides a
connection between extracellular survival signals and the factors
that induce apoptotic events within cells [21]. To investigate
whether the Akt pathway is involved in epirubicin-mediated
apoptosis, we examined the phosphorylation state of Akt in the
scrambled control cells and the GRP78 knockdown cells after
epirubicin treatment. Cell lysates were prepared, and the
phosphorylation level of Akt was analyzed by western blotting
with the anti-phospho-Akt (Thr308) antibody. Akt phosphoryla-
tion was decreased to a greater degree in the GRP78 knockdown
Figure 3. The effect of Nrf2 on epirubicin (epi) treatment. (A) Scrambled control and GRP78 knockdown DLD-1 cells were cultured for 48 h,
and nuclear Nrf2 expression was evaluated by western blotting. (B) The GRP78 knockdown DLD-1 cells were pretreated with scrambled siRNA (sc) or
Nrf2 siRNA for 24 h, and nuclear Nrf2 expression was evaluated by western blotting. (C) The GRP78 knockdown DLD-1 cells were pretreated with
scrambled siRNA (scramble) or Nrf2 siRNA for 24 h and treated with 500 ng/ml epirubicin (epi) for another 48 h. After treatment, the percentage of
cells that were in the subG1 phase indicated by DNA damage was determined as outlined in the Materials and Methods. These experiments were
performed at least 3 times, and a representative experiment is presented.
doi:10.1371/journal.pone.0035123.g003
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of epirubicin treatment (Figure 4A). We also investigated the
effects of epirubicin on Akt kinase activity using immunoprecip-
itation and western blotting techniques. Epirubicin inhibited the
phosphorylation level of GSK-3a/3b, (as was seen with the Akt
kinase activity) in both the scrambled control cells and the GRP78
knockdown cells, and the decrease in the Akt kinase activity
appeared to be enhanced in the GRP78 knockdown cells at 48 h
(Figure 4B). Because recent findings have suggested that the GSK-
3b protein, which is a key player in stress-responsive apoptosis, is
one of the downstream protein substrates for Akt kinase [22], the
epirubicin-induced suppression of Akt phosphorylation may
inhibit Akt-dependent phosphorylation of GSK-3b. To test this
possibility, total protein lysates prepared from epirubicin-treated
scrambled control cells and GRP78 knockdown cells were
subjected to immunoblotting with a phospho-GSK-3b antibody
that specifically recognizes GSK-3b phosphorylated on Ser-9.
Scrambled control cells and GRP78 knockdown cells exhibited
significant decreases in GSK-3b phosphorylation, and the highest
level of inhibition occurred in the GRP78 knockdown cells
incubated with epirubicin for 48 h (Figure 4C). These results
suggest that the inhibition of the Akt signaling cascade was
enhanced by the GRP78 knockdown in epirubicin-treated cells.
GRP78 knockdown enhanced the epirubicin-mediated
downregulation of the downstream targets of the Akt
pathway
We investigated whether inhibition of the Akt signaling pathway
had an effect on downstream targets in scrambled control cells and
GRP78 knockdown cells treated with epirubicin. b-catenin is a
GSK-3b target that is implicated in apoptotic resistance and
survival signaling [23], and increased expression of b-catenin has
been correlated with increased survival in cancer [23]. An
examination of b-catenin expression revealed that it was not
significantly changed in the scrambled control cells after 24 or
48 h of epirubicin treatment. A reduction in b-catenin expression,
however, was observed after 48 h of epirubicin treatment in the
GRP78 knockdown cells (Figure 5).
GRP78 knockdown enhanced protein phosphatase 2A
activity with epirubicin treatment
Various studies have demonstrated connections between the Akt
pathway and phosphatases. For example, PP2A has been shown to
Figure 4. The effect of the Akt pathway on epirubicin (epi) treatment. Scrambled control and GRP78 knockdown DLD-1 cells were treated
with epirubicin (500 ng/ml) for the indicated times. The phosphorylation of (A) Akt and (C) GSK 3b was evaluated by western blotting. (B) Akt activity
was determined as outlined in the Materials and Methods. The protein on the PVDF membrane stained with Coomassie brilliant blue is shown as an
internal control. These experiments were performed at least 3 times, and a representative experiment is presented.
doi:10.1371/journal.pone.0035123.g004
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Thr 308 and Ser 493 residues and block the Akt pathway [21]. We
further examined whether the expression and activity of PP2A was
involved in epirubicin-induced apoptosis in the scrambled control
cells and the GRP78 knockdown cells. Figure 6A shows that the
expression of PP2A decreased in the epirubicin-treated scrambled
control cells after 48 h of treatment. Conversely, the expression of
PP2A was increased at 24 h and did not decrease at 48 h in the
epirubicin-treated GRP78 knockdown cells. The activity of PP2A
was slightly decreased at 24 h and significantly decreased at 48 h
in the epirubicin-treated scrambled control cells. In contrast, PP2A
activity significantly increased approximately 2-fold at 24 h in the
epirubicin-treated GRP78 knockdown cells (Figure 6B). PP2A
activity did not significantly decrease at 48 h in the epirubicin-
treated GRP78 knockdown cells. These experiments demonstrated
a clear link between increased PP2A activity and the induction of
apoptosis via the inhibition of the Akt pathway in the GRP78
knockdown cells during epirubicin treatment. This highlighted the
importance of GRP78 knockdown for the inhibition of DLD-1
cells proliferation.
Discussion
A common characteristic of many cancers is their augmented
levels of ROS. The primary source of these ROS is increased
metabolic activity [21]. High ROS levels and Nrf2 nuclear
translocation in the GRP78 knockdown cells indicated that
GRP78 plays a redox homeostatic role in the DLD-1 cells. In
the presence of GRP78, epirubicin only induced a low level of
ROS (,2-fold) in DLD-1 cells, and a low level of ROS may result
in the activation of specific antioxidant systems in cancer cells that
can induce resistance to chemotherapy. Interestingly, the antiox-
idants DTT and PG both enhanced the apoptotic effect of
epirubicin in the scrambled control cells. The reduction of ROS
by epirubicin in the GRP78 knockdown cells highlighted the
possibility that increased ROS levels in DLD-1 cells may have a
direct effect on the cell survival pathways.
GRP78 is a chaperone that exists in the ER. In unstressed cells,
the ER transmembrane proteins (PERK and IRE1) are kept in an
inactive state via the attachment of GRP78 on their ER-lumenal
domains [24]. In general, the lumenal domains of the inactive
forms of PERK and IRE1 are comprised of 1:1 complexes with
GRP78 [25]. Once ER stress occurs, GRP78 disjoins and binds
with unfolded or misfolded proteins, which enables the homo-
oligomerization of PERK, IRE1 or both and results in the
autophosphorylation of these enzymes and the activation of their
substrates [24]. Nrf2 is a direct substrate of PERK and an effector
of PERK-dependent cell survival [26], which explains why the
GRP78 knockdown DLD-1 cells expressed a large amount of
nuclear Nrf2.
Nrf2 acts as a sensor for oxidative stress and regulates the
activation of defensive genes, which leads to the protection of cells
against the adverse effects of oxidative stress and promotes cell
survival [27]. In many cancer cells, Nrf2 shows pro-tumoral
characteristics that are similar to those of identical cytoprotective
genes that can increase cancer cell resistance to chemotherapeutic
drugs [8]. For example, Fluorouracil stimulates the Nrf2 pathway,
which modulates chemosensitivity and induces cytoprotective
genes in HT-29 colon cancer cells [9]. Nrf2 is a crucial
transcription factor that controls a protective response against
toxic insults from an extensive spectrum of chemical substances
[25]. In recent years, studies have demonstrated the role of Nrf2 in
protecting against both new and current chemotherapeutic drugs
in blood cancers [8]. Nrf2 overexpression has also been observed
in pancreatic cancer [7]. In addition, a study has shown that the
stable overexpression of Nrf2 in cancer cells induces an enhanced
level of resistance to chemotherapeutic agents, including doxoru-
bicin, etoposide and cisplatin [25]. Other reports have suggested
that the strategy of using Nrf2 inhibitors to augment the efficacy of
chemotherapeutic agents is not restricted to anticancer drugs or
certain cancer types. Indeed, Nrf2 inhibitors can be utilized during
chemotherapy to treat many cancer types [25]. The present study
revealed that apoptosis was enhanced by epirubicin treatment in
the Nrf2 siRNA-treated GRP78 knockdown cells, which suggests
that Nrf2 plays a critical defensive role in the GRP78 knockdown
cells.
A recent study revealed that the silencing of GRP78 gene
expression by RNAi suppressed the activation of Akt (i.e., Thr 308
phosphorylation) in 1-LN human prostate cancer cells [28]. In
addition, another study showed that the phosphorylation of Akt
was decreased in astrocytoma after transfection with GRP78
siRNA [29]. Lin et al. (2011) recently reported that Akt was a
downstream target of GRP78 in intervening cisplatin resistance in
ER-stress-tolerant human lung cancer cells [30]. These findings
indicated that the GRP78-directed Akt pathway plays an
important role in cancer survival. The present results showed that
GRP78 knockdown enhanced the inhibition of Akt activation with
epirubicin treatment in DLD-1 cells, which led to the inhibition of
downstream Akt substrates. The results of the present study
suggest that GRP78 knockdown may be a useful addition to the
arsenal of chemtherapeutic drugs that can be applied to promote
Figure 5. Expression of b-catenin after epirubicin (epi) treat-
ment. Scrambled control and GRP78 knockdown DLD-1 cells were
treated with epirubicin (500 ng/ml) for the indicated times, and the
expression of b-catenin was evaluated by western blotting. These
experiments were performed at least 3 times, and a representative
experiment is presented.
doi:10.1371/journal.pone.0035123.g005
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pathway.
The Akt pathway is constitutively active in many cancers, such
as skin, breast, prostate and colon cancer. After Akt activation, Akt
phosphorylates key survival proteins, such as the transcription
factor regulator GSK-3b. The phosphorylation of GSK-3b
decreases the susceptibility to apoptotic stresses in cancer cells.
The Akt signaling pathway is transduced via phosphorylation, and
phosphatases are the most important negative regulators. One
such phosphatase is PP2A, which can catalyze the opposite
reaction to Akt. Recently, a study demonstrated that exogenous
hydrogen peroxide could inhibit PP2A, and this resulted in the
activation of the Akt pathway [31]. Another study demonstrated
that cadmium-induced ROS also inhibited PP2A, which led to
activation of Erk1/2, JNK and apoptosis [32]. In line with these
observations, our data demonstrated that epirubicin treatment in
GRP78 knockdown DLD-1 cells decreased intracellular ROS and
activated PP2A. In addition, we showed that GSK-3b phosphor-
ylation and b-catenin expression were inhibited by epirubicin in
the GRP78 knockdown cells. Taken together, these results indicate
an important pathway involving ROS reduction and PP2A
activation, where epirubicin inhibits the Akt survival pathway
and enhances the apoptotic effect in the GRP78 knockdown cells.
Figure 6. Expression and activity of protein phosphatase 2A (PP2A) after epirubicin (epi) treatment. Scrambled control and GRP78
knockdown DLD-1 cells were treated with epirubicin (500 ng/ml) for the indicated times. (A) The expression of PP2A was evaluated by western
blotting, and (B) the activity of PP2A was determined as outlined in the Materials and Methods. These experiments were performed at least 3 times,
and a representative experiment is presented.
doi:10.1371/journal.pone.0035123.g006
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cells with compounds that have redox-lowering properties
increases their apoptotic susceptibility [21]. This suggests a great
potential for the use of antioxidants to decrease anti-apoptotic
pathways that are activated by low levels of ROS in cancer cells.
This finding is in agreement with our observation that the
antioxidants, DTT and PG both enhanced apoptosis in the
GRP78 scrambled cells. These redox-operating compounds can be
considered for use in combination with current clinical chemo-
therapeutic drugs to attain beneficial effects.
Epirubicin’s mechanism of cytotoxicity appears to involve the
production of ROS via significant reduction of catalase,
superoxide dismutase and cytosolic glutathione levels [33]. Several
oxidase enzymes, including nicotinamide-adenine dinucleotide
phosphate (NADPH) oxidase, xanthine oxidase, uncoupled
endothelial NO synthase (eNOS), cyclooxygenase, glucose oxidase,
and lipooxygenase can produce intracellular ROS. The mito-
chondrial electron transport also provides the source of intracel-
lular ROS [34]. In GRP78 knockdown DLD-1 cells, epirubicin
might damage or inhibit these ROS generated enzymes or induce
mitochondrial dysfunction and then reduce intracellular ROS. On
the other hand, epirubicin might increase superoxide dismutase,
catalase or cytosolic glutathione levels to reduce intracellular ROS
in GRP78 knockdown DLD-1 cells.
Our experimental results indicate that epirubicin increased
apoptosis in GRP78 knonkdown DLD-1 cells. In clinical
application, we can consider to use gene therapy to knockdown
the GRP78 expression in colon cancer cells accompany with
epirubicin chemotherapy. In addition, (-)-epigallocatechin gallate
(EGCG) has been found to directly interact with GRP78 at the
ATP-binding site of protein and regulate its function by competing
with ATP binding, resulting in the inhibition of ATPase activity.
EGCG binding results in the conversion of GRP78 from its active
monomer to the inactive dimer and oligomer forms [35]. The
combination of epirubicin and EGCG chemotherapy also can be
considered in clinical application.
In conclusion, GRP78 knockdown can change the oxidative
stress status of cancer cells. In the present study, this involved
increased intracellular ROS and Nrf2 nuclear translocation in
DLD-1 cells. Epirubicin enhanced apoptosis by reducing intra-
cellular ROS, activating PP2A and inhibiting the Akt survival
pathway in the GRP78 knockdown DLD-1 cells.
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